Apocrine carcinoma of the breast: A comprehensive review

Histology and Histopathology

Volumn 28, Issue 11, 2013, Pages 1393-1409

  Vranic, Semir ^a,b   Schmitt, Fernando ^c,d   Sapino, Anna ^b   Costa, Jose Luis ^d   Reddy, Sandeep ^e   Castro, Michael ^e   Gatalica, Zoran ^e  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b UNIVERSITY OF TURIN   (Italy)

^c Department of Pathology and Oncology ^*  (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e CARIS LIFE SCIENCES   (United States)

Author keywords

Androgen receptor; Apocrine carcinoma; Breast cancer; Special types

Indexed keywords

APOCRINE GLAND; BREAST TUMOR; CARCINOMA; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVIEW;

APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS;

EID: 84886296225     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (197)

1. Abati A., Kimmel M. and Rosen P. (1990). Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 94, 371-377.
2. Agoff S., Swanson P., Linden H., Hawes S. and Lawton T. (2003). Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120, 725-731.
3. Alexiev B., Boschnakova Z. and Prokopanov C. (1994). The apocrine carcinoma of the breast. A cytological, immunohistochemical and ultrastructural study of 6 cases. Zentralbl. Pathol. 140, 129-134.
4. Alvarenga C., Paravidino P., Alvarenga M., Dufloth R., Gomes M., Zeferino L. and Schmitt F. (2011). Expression of CK19 in invasive breast carcinomas of special histological types: implications for the use of one-step nucleic acid amplification. J. Clin. Pathol. 64, 493-497.
5. Alvarenga C., Paravidino P., Alvarenga M., Gomes M., Dufloth R., Zeferino L., Vassallo J. and Schmitt F. (2012). Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes. J. Clin. Pathol. 65, 1066-1071.
6. Aoyagi H., Ishida T., Yamada I., Kurebayashi J., Kurosumi M., Yokoe T., Ogawa T., Kawai T. and Izuo M. (1990). Ten cases of an apocrine carcinoma of the breast and a review of cases in the Japanese literature. Gan. no. rinsho. 36, 681-689.
7. Arnould N., Pouget O., Gharbi M. and Brettes J.P. (2006). Breast cancer in men: are there similarities with breast cancer in women? Gynécologie Obstétrique Fertilité 34, 413-419.
8. Baehner F., Achacoso N., Maddala T., Shak S., Quesenberry C., Goldstein L., Gown A. and Habel L. (2010). Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J. Clin. Oncol. 28, 4300-4306.
9. Banneau G., Guedj M., MacGrogan G., de Mascarel I., Velasco V., Schiappa R., Bonadona V., David A., Dugast C., Gilbert-Dussardier B., Ingster O., Vabres P., Caux F., de Reynies A., Iggo R., Sevenet N., Bonnet F. and Longy M. (2010). Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast. Cancer. Res. 12, R63.
10. Bhargava R., Gerald W., Li A., Pan Q., Lal P., Ladanyi M. and Chen B. (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18, 1027-1033.
11. Bhargava R., Striebel J., Beriwal S., Flickinger J., Onisko A., Ahrendt G. and Dabbs D. (2009). Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int. J. Clin. Exp. Pathol. 2, 444-455.
12. Bhargava R., Beriwal S., Striebel J. and Dabbs D. (2010). Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl. Immunohistochem. Mol. Morphol. 18, 113-118.
13. Bhargava R., Beriwal S., McManus K. and Dabbs D. (2011). Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 19, 218-225.
14. Bratthauer G., Lininger R., Man Y. and Tavassoli F. (2002). Androgen and estrogen receptor mRNA status in apocrine carcinomas. Diagn. Mol. Pathol. 11, 113-118.
15. Bryant J. (1981). Male breast cancer: a case of apocrine carcinoma with psammoma bodies. Hum. Pathol. 12, 751-753.
16. Bundred N.J., Stewart H.J., Shaw D.A., Forrest A.P. and Miller W.R. (1990). Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer. Eur. J. Cancer. 26, 1145-1147.
17. Bundred N., Walker R., Everington D., White G., Stewart H. and Miller W. (1990). Is apocrine differentiation in breast carcinoma of prognostic significance? Br. J. Cancer 62, 113-117.
18. Castellano I., Allia E., Accortanzo V., Vandone A., Chiusa L., Arisio R., Durando A., Donadio M., Bussolati G., Coates A., Viale G. and Sapino A. (2010). Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer. Res. Treat. 124, 607-617.
19. Celis J., Gromova I., Gromov P., Moreira J., Cabezón T., Friis E. and Rank F. (2006). Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 580, 29359-2944.
20. Celis J., Gromov P., Cabezón T., Moreira J., Friis E., Jirström K., Llombart-Bosch A., Timmermans-Wielenga V., Rank F. and Gromova I. (2008). 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol. Cell. Proteomics 7, 1795-1809.
21. Celis J., Cabezón T., Moreira J., Gromov P., Gromova I., Timmermans-Wielenga V., Iwase T., Akiyama F., Honma N. and Rank F. (2009). Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol. Oncol. 3, 220-237.
22. Cha Y., Jung W.H. and Koo J. (2012). The clinicopathologic features of molecular apocrine breast cancer. Korean J. Pathol. 46, 169-176.
23. Chandarlapaty S., Sakr R., Giri D., Patil S., Heguy A., Morrow M., Modi S., Norton L., Rosen N., Hudis C. and King T. (2012). Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clin. Cancer. Res. 18, 6784-6791.
24. Charpin C., Dales J.P., Garcia S., Carpentier S., Djemli A., Andrac L., Lavaut M.N., Allasia C. and Bonnier P. (2004). Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin. Cancer Res. 10, 5815-5819.
25. Chen Y.Y., Hwang E.S., Roy R., DeVries S., Anderson J., Wa C., Fitzgibbons P., Jacobs T., MacGrogan G., Peterse H., Vincent-Salomon A., Tokuyasu T., Schnitt S. and Waldman F. (2009). Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am. J. Surg. Pathol. 33, 1683-1694.
26. Chia K., Liu J., Francis G. and Naderi A. (2011). A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13, 154-166.
27. Choi J., Jung W.H. and Koo J. (2012). Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol. Histopathol. 27, 1481-1493.
28. Choi J., Jung W. and Koo J. (2013). Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 62, 275-286.
29. Cimino-Mathews A., Hicks J.L., Illei P.B., Halushka M.K., Fetting J.H., De Marzo A.M., Park B.H. and Argani P. (2012). Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum. Pathol. 43, 1003-1011
30. Collins L., Cole K., Marotti J., Hu R., Schnitt S. and Tamimi R. (2011). Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod. Pathol. 24, 924-931.
31. Currie M.J., Beardsley B.E., Harris G.C., Gunningham S.P., Dachs G.U., Dijkstra B., Morrin H.R., Wells J.E. and Robinson B.A. (2013). Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum. Pathol. 44, 402-411.
32. d'Amore E., Terrier-Lacombe M., Travagli J., Friedman S. and Contesso G. (1988). Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res. Treat. 12, 37-44.
33. Dag A., Serinsoz E. and Ocal K. (2012). Apocrine carcinoma of the male breast. Surg. Practice 16:160-163.
34. Damiani S., Cattani M., Buonamici L. and Eusebi V. (1998). Mammary foam cells. Characterization by immunohistochemistry and in situ hybridization. Virchows. Arch. 432, 433-440.
35. de Beça F., Caetano P., Gerhard R., Alvarenga C., Gomes M., Paredes J. and Schmitt F. (2013). Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J. Clin. Pathol. 66, 187-191.
36. Dellapasqua S., Maisonneuve P., Viale G., Pruneri G., Mazzarol G., Ghisini R., Mazza M., Iorfida M., Rotmensz N., Veronesi P., Luini A., Goldhirsch A. and Colleoni M. (2013). Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. Clin. Breast. Cancer. 13, 95-102.
37. Diaz de Leon E., Carcangiu M., Prieto V., McCue P., Burchette J., To G., Norris B., Kovatich A., Sanchez R., Krigman H. and Gatalica Z. (2000). Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor. Am. J. Clin. Pathol. 113, 572-575.
38. Doane A., Danso M., Lal P., Donaton M., Zhang L., Hudis C. and Gerald W. (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008.
39. Dreyer G., Vandorpe T., Smeets A., Forceville K., Brouwers B., Neven P., Janssens H., Deraedt K., Moerman P., Van Calster B., Christiaens M.R., Paridaens R. and Wildiers H. (2013). Triple negative breast cancer: Clinical characteristics in the different histological subtypes. Breast (in press).
40. Dumay A., Feugeas J.P., Wittmer E., Lehmann-Che J., Bertheau P., Espié M., Plassa L.F., Cottu P., Marty M., André F., Sotiriou C., Pusztai L. and de Thé H. (2013). Distinct tumor protein p53 mutants in breast cancer subgroups. Int. J. Cancer 132, 1227-1231.
41. Durham J. and Fechner R. (2000). The histologic spectrum of apocrine lesions of the breast. Am. J. Clin. Pathol. 113, S3-S18.
42. Elayat G., Selim A.G.A. and Wells C. (2009a). Alterations of the cell cycle regulators cyclin D1, cyclin A, p27, p21, p16, and pRb in apocrine metaplasia of the breast. Breast J. 15, 475-482.
43. Elayat G., Selim A.G. and Wells C.A. (2009b). Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology 54, 348-354.
44. Elayat G., Selim A.G.A., Gorman P., Tomlinson I. and Wells C. (2011). Cyclin D-1 protein over-expression is not associated with gene amplification in benign and atypical apocrine lesions of the breast. Pathol. Res. Pract. 207, 75-78.
45. Elston C. and Ellis I. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410.
46. Eusebi V., Betts C., Haagensen D., Gugliotta P., Bussolati G. and Azzopardi J. (1984). Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum. Pathol. 15, 134-140.
47. Eusebi V., Millis R., Cattani M., Bussolati G. and Azzopardi J. (1986). Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 123, 532-541.
48. Eusebi V., Magalhaes F. and Azzopardi J.G. (1992). Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrinedifferentiation. Hum. Pathol. 23, 655-662.
49. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., Macgrogan G., Bergh J., Cameron D., Goldstein D., Duss S., Nicoulaz A.L., Brisken C., Fiche M., Delorenzi M. and Iggo R. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660-4671.
50. Feuerhake F., Unterberger P. and Höfter E. (2001). Cell turnover in apocrine metaplasia of the human mammary gland epithelium: apoptosis, proliferation, and immunohistochemical detection of Bcl-2, Bax, EGFR, and c-erbB2 gene products. Acta Histochem. 103, 53-65.
51. Foley J., Nickerson N., Nam S., Allen K., Gilmore J., Nephew K. and Riese D. (2010). EGFR signaling in breast cancer: bad to the bone. Semin. Cell. Dev. Biol. 21, 951-960.
52. Fountzilas G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., Malamou-Mitsi V., Miliaras S., Chrisafi S., Papadopoulos S., Sotiropoulou M., Filippidis T., Gogas H., Koletsa T., Bafaloukos D., Televantou D., Kalogeras K., Pectasides D., Skarlos D., Koutras A. and Dimopoulos M.A. (2012). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PloS One 7, e37946.
53. Frable W. and Kay S. (1968). Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 21, 756-763.
54. Gatalica Z. (1997). Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 193, 753-758.
55. Gatalica Z. and Tawfik O. (2006). Pure apocrine carcinomas of the breast are characterized by consistent aneuploidy, high proliferative fraction and overexpression of Her-2 and p53. Mod. Pathol. 19, 27A. (Abstract)
56. Gennari A., Sormani M., Pronzato P., Puntoni M., Colozza M., Pfeffer U. and Bruzzi P. (2008). HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl. Cancer Inst. 100, 14-20.
57. Gerhard R., Costa J. and Schmitt F. (2012). Benign and malignant apocrine lesions of the breast. Expert Rev. Anticancer Ther. 12, 215-221.
58. Gilles R., Lesnik A., Guinebretière J., Tardivon A., Masselot J., Contesso G. and Vanel D. (1994). Apocrine carcinoma: clinical and mammographic features. Radiology 190, 495-497.
59. Grekou A., Stravoravdi P., Patakiouta F. and Toliou T. (1999). Intranuclear helioid inclusions in a case of breast carcinoma. Breast J. 5, 63-64.
60. Grob T., Heilenkötter U., Geist S., Paluchowski P., Wilke C., Jaenicke F., Quaas A., Wilczak W., Choschzick M., Sauter G. and Lebeau A. (2012). Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res. Treat. 134, 561-567.
61. Gucalp A. and Traina T.A. (2010). Triple-negative breast cancer: role of the androgen receptor. Cancer J. 16, 62-65.
62. Guedj M., Marisa L., de Reynies A., Orsetti B., Schiappa R., Bibeau F., MacGrogan G., Lerebours F., Finetti P., Longy M., Bertheau P., Bertrand F., Bonnet F., Martin A., Feugeas J., Bièche I., Lehmann-Che J., Lidereau R., Birnbaum D., Bertucci F., de Thé H. and Theillet C. (2012). A refined molecular taxonomy of breast cancer. Oncogene 31, 1196-1206.
63. Gupta D., Croitoru C., Ayala A., Sahin A. and Middleton L. (2002). E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. Ann. Diagn. Pathol. 6, 141-147.
64. Gwin K., Lezon-Geyda K., Harris L. and Tavassoli F. (2011). Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation. Int. J. Surg. Pathol. 19, 20-25.
65. Haagensen D., Dilley W., Mazoujian G. and Wells S. (1990). Review of GCDFP-15. An apocrine marker protein. Ann. N.Y. Acad. Sci. 586, 161-173.
66. Hasegawa M., Moritani S., Murakumo Y., Sato T., Hagiwara S., Suzuki C., Mii S., Jijiwa M., Enomoto A., Asai N., Ichihara S. and Takahashi M. (2008). CD109 expression in basal-like breast carcinoma. Pathol. Int. 58, 288-294.
67. Hickey T., Robinson J.L., Carroll J. and Tilley W. (2012). Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol. Endocrinol. 26, 1252-1267.
68. Honma N., Sakamoto G., Akiyama F., Esaki Y., Sawabe M., Arai T., Hosoi T., Harada N., Younes M. and Takubo K. (2003). Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 42, 120-127.
69. Honma N., Takubo K., Akiyama F., Sawabe M., Arai T., Younes M., Kasumi F. and Sakamoto G. (2005). Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47, 195-201.
70. Honma N., Takubo K., Arai T., Younes M., Kasumi F., Akiyama F. and Sakamoto G. (2006). Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS 114, 712-719.
71. Honma N., Takubo K., Akiyama F., Kasumi F., Sawabe M., Arai T., Hosoi T., Yoshimura N., Harada N., Younes M. and Sakamoto G. (2007). Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology 50, 425-433.
72. Honma N., Saji S., Kurabayashi R., Aida J., Arai T., Horii R., Akiyama F., Iwase T., Harada N., Younes M., Toi M., Takubo K. and Sakamoto G. (2008). Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS 116, 923-930.
73. Hu R., Dawood S., Holmes M., Collins L., Schnitt S., Cole K., Marotti J., Hankinson S., Colditz G. and Tamimi R. (2011). Androgen receptor expression and breast cancer survival in postmenopausal women. Clin. Cancer Res. 17, 1867-1874.
74. Iggo R. (2011). New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours. Breast Cancer Res. 13, 318.
75. Iizuka M., Enomoto K. and Sakurai K. (2012). A case of breast cancer treated with neoadjuvant chemotherapy and segmentectomy. Gan. To. Kagaku. Ryoho. 39, 2027-2029.
76. Isola J. (1993). Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170, 31-35.
77. Iwase H., Kurebayashi J., Tsuda H., Ohta T., Kurosumi M., Miyamoto K., Yamamoto Y. and Iwase T. (2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17, 118-124.
78. Jang K.S., Han H.X., Paik S.S., Brown P.H. and Kong G. (2006). Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 244, 203-210.
79. Japaze H., Emina J., Diaz C., Schwam R., Gercovich N., Demonty G., Morgenfeld E., Rivarola E., Gil Deza E. and Gercovich F. (2005). 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 14, 3-10.
80. Jones C., Damiani S., Wells D., Chaggar R., Lakhani S. and Eusebi V. (2001). Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 158, 207-214.
81. Karameris A., Worthy E., Gorgoulis V., Quezado M. and Anastassiades O. (1995). p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J. Pathol. 176, 361-372.
82. Kasami M., Gobbi H., Dupont W., Simpson J., Page D. and Vnencak-Jones C. (2000). Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. Breast 9, 23-27.
83. Kasashima S., Kawashima A., Ozaki S. and Nakanuma Y. (2012). Expression of 5·-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness. Histopathology 60, E51-E57.
84. Kaya H., Bozkurt S., Erbarut I. and Djamgoz M. (2008). Apocrine carcinomas of the breast in Turkish women: hormone receptors, cerbB-2 and p53 immunoexpression. Pathol. Res. Pract. 204, 367-371.
85. Kim S., Jung W. and Koo J. (2012). Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumour Biol. 33, 1681-1694.
86. Koletsa T., Kotoula V., Karayannopoulou G., Nenopoulou E., Karkavelas G., Papadimitriou C. and Kostopoulos I. (2010). EGFR expression and activation are common in HER2 positive and triple-negative breast tumours. Histol. Histopathol. 25, 1171-1179.
87. Konecny G. (2012). Emerging strategies for the dual inhibition of HER2-positive breast cancer. Curr. Opin. Obstet. Gynecol. 25, 55-65.
88. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H. and van de Vijver M. (2007). Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9, R65.
89. Laforga J., Gasent J. and Sánchez I. (2011). Encapsulated apocrine papillary carcinoma of the breast: case report with clinicopathologic and immunohistochemical study. Diagn. Cytopathol. 39, 288-293.
90. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H. and van de Vijver M.J. (2012). WHO classification of tumours of the breast. IARC.Lyon.
91. Lambot M.A., Eddafali B., Simon P., Fayt I. and Noël J.C. (2001). Metastasis from apocrine carcinoma of the breast to an endometrial polyp. Virchows Arch. 438, 517-518.
92. Leal C., Henrique R., Monteiro P., Lopes C., Bento M., De Sousa C., Lopes P., Olson S., Silva M. and Page D. (2001). Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum. Pathol. 32, 487-493.
93. Lehmann B.D., Bauer J.A., Chen Xi., Sanders M.E., Chakravarthy A.B., Shyr Y. and Pietenpol J.A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767.
94. Lewis G., Subhawong A., Nassar H., Vang R., Illei P., Park B. and Argani P. (2011). Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am. J. Clin. Pathol. 135, 587-591.
95. Liegl B., Horn L.C. and Moinfar F. (2005). Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Mod. Pathol. 18, 1283-1288.
96. Lininger R., Zhuang Z., Man Y., Park W., Emmert-Buck M. and Tavassoli F. (1999). Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Mod. Pathol. 12, 1083-1089.
97. Lobaccaro J., Lumbroso S., Belon C., Galtier-Dereure F., Bringer J., Lesimple T., Namer M., Cutuli B., Pujol H. and Sultan C. (1993). Androgen receptor gene mutation in male breast cancer. Hum. Mol. Genet. 2, 1799-1802.
98. Lu Y., Zi X., Zhao Y., Mascarenhas D. and Pollak M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer. Inst. 93, 1852-1857.
99. Mardi K., Sharma J. and Sharma N. (2004). Apocrine carcinoma of the breast presenting as a solitary cyst: cytological and histopathological study of a case. Indian J. Pathol. Microbiol. 47, 268-270.
100. Martin V., Botta F., Zanellato E., Molinari F., Crippa S., Mazzucchelli L. and Frattini M. (2012). Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol. Histopathol. 27, 785-792.
101. Maruyama N., Miyoshi Y., Taguchi T., Tamaki Y., Monden M. and Noguchi S. (2007). Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin. Cancer Res. 13, 408-414.
102. Masood S. and Rosa M. (2009). The challenge of apocrine proliferations of the breast: a morphologic approach. Pathol. Res. Pract. 205, 155-164.
103. Masuda H., Zhang D., Bartholomeusz C., Doihara H., Hortobagyi G. and Ueno N. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 136, 331-345.
104. Matsubara N., Mukai H., Fujii S. and Wada N. (2013). Different prognostic significance of Ki-67 change between pre-and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res. Treat. 137, 203-212.
105. Matsuo K., Fukutomi T., Tsuda H., Kanai Y., Tanaka S.A. and Nanasawa T. (1998). Apocrine carcinoma of the breast: Clinicopathological analysis and histological subclassification of 12 cases. Breast Cancer 5, 279-284.
106. Matsuo K., Fukutomi T., Hasegawa T., Akashi-Tanaka S., Nanasawa T. and Tsuda H. (2002). Histological and immunohistochemical analysis of apocrine breast carcinoma. Breast Cancer 9, 43-49.
107. Mazoujian G., Bodian C., Haagensen D. and Haagensen C. (1989). Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors. Cancer 63, 2156-2161.
108. McGhan L.J., McCullough A.E., Protheroe C.A., Dueck A.C., Lee J.J., Nunez R., Castle E.P., Gray R.J., Wasif N., Goetz M.P., Hawse J.R., Henry T.J., Barrett M.T., Heather C.E. and Pockaj B.A. (2012). Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Ann. Surg. Oncol. 19 (suppl.1), S12. (Abstract)
109. Micello D., Marando A., Sahnane N., Riva C., Capella C. and Sessa F. (2010). Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch. 457, 467-476.
110. Middleton L.P., Palacios D.M., Bryant B.R., Krebs P., Otis C.N. and Merino M.J. (2000). Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am. J. Surg. Pathol. 24, 1650-1656.
111. Miller W., Telford J., Dixon J. and Shivas A. (1985). Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res. Treat. 5, 67-73.
112. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax S., Weybora W., Ratschek M., Tavassoli F. and Denk H. (2003). Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98, 703-711.
113. Monhollen L., Morrison C., Ademuyiwa F., Chandrasekhar R. and Khoury T. (2012). Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology 61, 365-377.
114. Montagna E., Maisonneuve P., Rotmensz N., Cancello G., Iorfida M., Balduzzi A., Galimberti V., Veronesi P., Luini A., Pruneri G., Bottiglieri L., Mastropasqua M., Goldhirsch A., Viale G. and Colleoni M. (2013). Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin. Breast Cancer 13, 31-39.
115. Moore N., Buchanan G., Harris J., Selth L., Bianco-Miotto T., Hanson A., Birrell S., Butler L., Hickey T. and Tilley W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr. Relat. Cancer 19, 599-613.
116. Moritani S., Ichihara S., Hasegawa M., Endo T., Oiwa M., Shiraiwa M., Nishida C., Morita T., Sato Y., Hayashi T. and Kato A. (2011). Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipid-rich carcinoma. Am. J. Surg. Pathol. 35, 861-867.
117. Moriya T., Sakamoto K., Sasano H., Kawanaka M., Sonoo H., Manabe T. and Ito J. (2000). Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 13, 13-18.
118. Mossler J., Barton T., Brinkhous A., McCarty K., Moylan J. and McCarty K. (1980). Apocrine differentiation in human mammary carcinoma. Cancer 46, 2463-2471.
119. Naderi A. and Hughes-Davies L. (2008). A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10, 542-548.
120. Naderi A. and Liu J. (2010). Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett. 298, 74-87.
121. Naderi A., Chia K. and Liu J. (2011). Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 13, R36.
122. Naderi A. and Meyer M. (2012). Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 14, R111.
123. Nagao T., Kinoshita T., Hojo T., Tsuda H., Tamura K. and Fujiwara Y. (2012). The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 21, 289-295.
124. Narita D., Anghel A., Cimpean A., Izvernariu D., Cireap N., Ilina R. and Ursoniu S. (2010). Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer. Neoplasm 57, 198-206.
125. Ni M., Chen Y., Lim E., Wimberly H., Bailey S., Imai Y., Rimm D., Liu X. and Brown M. (2011). Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20, 119-131.
126. Niemeier L., Dabbs D., Beriwal S., Striebel J. and Bhargava R. (2010). Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23, 205-212.
127. Niu D., Kondo T., Nakazawa T., Yamane T., Mochizuki K., Kawasaki T., Matsuzaki T., Takata K. and Katoh R. (2012). Expression of aquaporin3. In: Breast Pathology. 2nd ed. O'Malley F.P., Pinder S.E. and Mulligan A.M. (eds). Elsevier Saunders.
128. O'Malley F. and Bane A. (2004). The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 11, 1-9.
129. O'Malley F. and Bane A. (2008). An update on apocrine lesions of the breast. Histopathology. 52, 3-10.
130. O'Malley F.P., Pinder S.E. and Muligan A.M. (2011). Breast Pathology. 2nd edition. Saunders Elsevier.
131. Pagani A., Sapino A., Eusebi V., Bergnolo P. and Bussolati G. (1994). PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virchows Arch. 425, 459-465.
132. Page D.L. (2005). Apocrine carcinomas of the breast. Breast 14, 1-2.
133. Palacios J., Sarrió D., García-Macias M.C., Bryant B., Sobel M.E. and Merino M.J. (2003). Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod. Pathol. 16, 674-678.
134. Paredes J., Correia A.L., Ribeiro A.S., Milanezi F., Cameselle-Teijeiro J. and Schmitt F.C. (2008). Breast carcinomas that co-express E-and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J. Clin. Pathol. 61, 856-862.
135. Park S., Koo J., Kim M., Park H., Lee J., Lee J., Kim S., Park B. and Lee K. (2011). Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann. Oncol. 22, 1755-1762.
136. Perou C., Sørlie T., Eisen M., van de Rijn M., Jeffrey S., Rees C., Pollack J., Ross D., Johnsen H., Akslen L., Fluge O., Pergamenschikov A., Williams C., Zhu S., Lønning P., Børresen-Dale A., Brown P. and Botstein D. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
137. Phuah S.Y., Looi L.M., Hassan N., Rhodes A., Dean S., Taib N., Yip C.H. and Teo S.H. (2012). Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Res. 14, R142.
138. Rakha E., Putti T., Abd El-Rehim D., Paish C., Green A., Powe D., Lee A., Robertson J. and Ellis I. (2006). Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 208, 495-506.
139. Rakha E., El-Sayed M., Green A., Lee A., Robertson J. and Ellis I. (2007). Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32.
140. Reis-Filho J.S., Simpson P.T., Jones C., Steele D., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Lambros M., Ashworth A., Palacios J., Schmitt F. and Lakhani S.R. (2005). Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 207, 1-13.
141. Robinson J.L., Macarthur S., Ross-Innes C., Tilley W., Neal D., Mills I. and Carroll J. (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30, 3019-3027.
142. Roddy H. and Silverberg S. (1980). Ultrastructural analysis of apocrine carcinoma of the human breast. Ultrastruct. Pathol. 1, 385-393.
143. Roldán G., Delgado L. and Musé I. (2006). Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer Biol. Ther. 5, 505-510.
144. Rosen P.P. and Hoda S.A. (2006). Breast Pathology: Diagnosis by needle core biopsy. 2nd ed. Lippincott Williams and Wilkins.
145. Rosenfeldt M. and Ryan K. (2011). The multiple roles of autophagy in cancer. Carcinogenesis 32, 955-963.
146. Ross J. (2010). Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference? J. Clin. Oncol. 28, 4293-4295.
147. Rydén L., Jirström K., Haglund M., Stål O. and Fernö M. (2010). Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res. Treat. 120, 491-498.
148. Sakamoto G. and Honma N. (2009). Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer. Breast Cancer 16, 281-282.
149. Salvucci O., Bouchard A., Baccarelli A., Deschênes J., Sauter G., Simon R., Bianchi R. and Basik M. (2006). The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat. 97, 275-283.
150. Sanga S., Broom B., Cristini V. and Edgerton M. (2009). Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med. Genomics 2, 59.
151. Sapino A., Righi L., Cassoni P., Papotti M., Gugliotta P. and Bussolati G. (2001). Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod. Pathol. 14, 768-776.
152. Sapp M., Malik A. and Hanna W. (2003). Hormone receptor profile of apocrine lesions of the breast. Breast J. 9, 335-336.
153. Schmitt F., Soares R. and Seruca R. (1998). Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours. Virchows Arch. 433, 505-509.
154. Schmitt F.C. and Reis-Filho J.S. (2002). Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? Breast 11, 463-465.
155. Seal M., Wilson C., Naus G., Chia S., Bainbridge T. and Hayes M. (2009). Encapsulated apocrine papillary carcinoma of the breast-a tumour of uncertain malignant potential: report of five cases. Virchows Arch. 455, 477-483.
156. Selim A. and Wells C. (1999). Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 52, 838-841.
157. Selim A.G., El-Ayat G. and Wells C.A. (2000). c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. J. Pathol. 191, 138-142.
158. Selim A.G., El-Ayat G., Naase M. and Wells C.A. (2002). C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast 11, 466-472.
159. Shah D., Persaud V. and Coard K. (1980). Apocrine carcinoma of the male breast. West Indian Med. J. 29, 272-276.
160. Shan L., Yang Q., Nakamura M., Nakamura Y., Mori I., Sakurai T. and Kakudo K. (2000). Active allele loss of the androgen receptor gene contributes to loss of androgen receptor expression in female breast cancers. Biochem. Biophys. Res. Commun. 275, 488-492.
161. Shao M.M., Zhang F., Meng G., Wang X.X., Xu H., Yu X.W., Chen L.Y. and Tse G. (2011). Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. Histopathology 59, 264-273.
162. Shao M.M., Chan S., Yu A., Lam C., Tsang J., Lui P., Law B., Tan P.H. and Tse G. (2012). Keratin expression in breast cancers. Virchows Arch. 461, 313-322.
163. Shim H., Jung W., Kim H., Park K. and Cho N. (2006). Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS 114, 352-358.
164. Simpson P.T., Reis-Filho J.S., Lambros M.B., Jones C., Steele D., Mackay A., Iravani M., Fenwick K., Dexter T., Jones A., Reid L., Da Silva L., Shin S.J., Hardisson D., Ashworth A., Schmitt F.C., Palacios J. and Lakhani S.R. (2008). Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J. Pathol. 215, 231-244.
165. Singh G., Odriozola L., Guan H., Kennedy C. and Chan A. (2011). Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line. BMC Cancer 11, 490.
166. Sørlie T., Perou C., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M., van de Rijn M., Jeffrey S., Thorsen T., Quist H., Matese J., Brown P., Botstein D., Lønning P. and Børresen-Dale A. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874.
167. Sørlie T., Tibshirani R., Parker J., Hastie T., Marron J., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C., Lønning P., Brown P., Børresen-Dale A.L. and Botstein D. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423.
168. Steelman L., Navolanic P., Sokolosky M., Taylor J., Lehmann B., Chappell W., Abrams S., Wong E., Stadelman K., Terrian D., Leslie N., Martelli A., Stivala F., Libra M., Franklin R. and McCubrey J. (2008). Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27, 4086-4095.
169. Syrjäkoski K., Hyytinen E.R., Kuukasjärvi T., Auvinen A., Kallioniemi O.P., Kainu T. and Koivisto P. (2003). Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res. Treat. 77, 167-170.
170. Takeuchi H., Tsuji K., Ueo H., Kano T. and Maehara Y. (2004). Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women. Breast Cancer Res. Treat. 88, 49-54.
171. Tan P., Harada O., Thike A. and Tse G. (2011). Histiocytoid breast carcinoma: an enigmatic lobular entity. J. Clin. Pathol. 64, 654-659.
172. Tanaka K., Imoto S., Wada N., Sakemura N. and Hasebe K. (2008). Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 14, 164-168.
173. Tavassoli F.A. (1999). Pathology of the breast. 2nd ed. McGraw-Hill.
174. Tavassoli F.A., Purcell C.A., Bratthauer G.L. and Man Y. (1996). Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: Implications for therapy. Breast J. 2, 261-269.
175. Trigueros-Motos L., Pérez-Torras S., Casado F.J., Molina-Arcas M. and Pastor-Anglada M. (2012). Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. BMC Cancer. 12, 434.
176. Tsutsumi Y. (2012). Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn. J. Clin. Oncol. 42, 375-386.
177. Unal E., Firat A., Gunes P., Kilicoglu G., Gulkilik A. and Titiz I. (2007). Apocrine carcinoma of the breast: clinical, radiologic, and pathologic correlation. Breast J. 13, 617-618.
178. Varga Z., Zhao J., Ohlschlegel C., Odermatt B. and Heitz P. (2004). Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology. 44, 332-338.
179. Vranic S., Tawfik O., Palazzo J., Bilalovic N., Eyzaguirre E., Lee L., Adegboyega P., Hagenkord J. and Gatalica Z. (2010). EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod. Pathol. 23, 644-653.
180. Vranic S., Gatalica Z., Deng H., Frkovic-Grazio S., Lee L., Gurjeva O. and Wang Z.Y. (2011a). ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J. Clin. Pathol. 64, 54-57.
181. Vranic S., Teruya B., Repertinger S., Ulmer P., Hagenkord J. and Gatalica Z. (2011b). Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117, 48-53.
182. Vranic S., Gatalica Z. and Wang Z.Y. (2011c). Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol. Lett. 2, 1131-1137.
183. Vranic S., Gurjeva O., Frkovic-Grazio S., Palazzo J., Tawfik O. and Gatalica Z. (2011d). IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. Appl. Immunohistochem. Mol. Morphol. 19, 413-416.
184. Wang Z., Zhang X., Shen P., Loggie B., Chang Y. and Deuel T. (2006). A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. USA 103, 9063-9068.
185. Wang Y., Romigh T., He X., Tan M.H., Orloff M., Silverman R., Heston W. and Eng C. (2011a). Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30, 4327-4338.
186. Wang L., Zhang Q., Zhang J., Sun S., Guo H., Jia Z., Wang B., Shao Z., Wang Z. and Hu X. (2011b). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11, 248.
187. Weigelt B. and Reis-Filho J. (2009). Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 6, 718-730.
188. Weigelt B., Horlings H., Kreike B., Hayes M., Hauptmann M., Wessels L., de Jong D., Van de Vijver M., Van't Veer L. and Peterse J. (2008). Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216, 141-150.
189. Weigelt B., Geyer F. and Reis-Filho J. (2010a). Histological types of breast cancer: how special are they? Mol. Oncol. 4, 192-208.
190. Weigelt B., Geyer F.C., Natrajan R., Lopez-Garcia M.A., Ahmad A.S., Savage K., Kreike B. and Reis-Filho J.S. (2010b). The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J. Pathol. 220, 45-57.
191. Wells C. and El-Ayat G. (2007). Non-operative breast pathology: apocrine lesions. J. Clin. Pathol. 60, 1313-1320.
192. Wen Y., Ho A., Patil S., Akram M., Catalano J., Eaton A., Norton L., Benezra R. and Brogi E. (2012). Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res. Treat. 135, 93-102.
193. Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., Barrett-Lee P., Easton D., Ponder B. and Stratton M. (1992). A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat. Genet. 2, 132-134.
194. Yan M., Rayoo M., Takano E. and Fox S. (2011). Nuclear and cytoplasmic expressions of ER'1 and ER'2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res. Treat. 126, 395-405.
195. Yeh I.T., Martin M., Robetorye R., Bolla A., McCaskill C., Shah R., Gorre M., Mohammed M. and Gunn S. (2009). Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 22, 1169-1175.
196. Zagorianakou P., Zagorianakou N., Stefanou D., Makrydimas G. and Agnantis N. (2006). The enigmatic nature of apocrine breast lesions. Virchows Arch. 448, 525-531.
197. Zhang X., Kang L., Ding L., Vranic S., Gatalica Z. and Wang Z.Y. (2011). A positive feedback loop of ER-·36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30, 770-780.